Anadrol vs MK-2866
FDA Approved vs Moderate Research
avoid Mechanism-based · 64% Both Anadrol and MK-2866 carry hepatotoxic risk. Combining hepatotoxic compounds significantly increases liver damage potential. If unavoidable, include liver support (TUDCA/NAC) and monitor ALT/AST frequently.
Molecular Data
Anadrol MK-2866
Weight 332.48 Da 389.33 Da
Half-life ~8-9 hours ~24 hours
Type 17-alpha alkylated anabolic steroid (C21H32O3) Non-steroidal selective androgen receptor modulator (C19H14F3N3O3)
Key Benefits
Anadrol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Exceptional strength gains, often noticeable within the first week
03 Potent stimulation of erythropoietin and red blood cell production
04 Increased appetite and nutrient partitioning in some users
05 Improved recovery between training sessions
06 Full, round muscle appearance due to intramuscular water and glycogen retention
07 FDA-approved treatment for various forms of anemia
MK-2866
01 Increases lean body mass in a dose-dependent manner with clinical trial support
02 Preserves muscle mass during caloric deficit or catabolic conditions
03 Selective tissue activity reduces androgenic side effects compared to anabolic steroids
04 Oral bioavailability eliminates the need for injections
05 Does not aromatize to estrogen, avoiding gynecomastia and water retention
06 Improves physical function and stair-climbing power in clinical populations
07 Long 24-hour half-life allows convenient once-daily dosing
08 Mild side effect profile at commonly studied doses
Side Effects
Anadrol
Significant water retention and bloating (estrogenic, not aromatase-mediated)
Elevated blood pressure (fluid volume and RBC increase)
Severe liver stress and elevated liver enzymes (AST/ALT)
Back pumps and lower back pain during exercise
Headaches (often blood pressure-related)
Appetite suppression (paradoxical for a mass-building compound)
Lethargy and fatigue (hepatic strain-related)
Acne and oily skin
Suppression of natural testosterone production
MK-2866
Mild testosterone suppression (dose-dependent, typically 10-30% reduction at 25 mg)
HDL cholesterol reduction (10-20% suppression observed in clinical trials)
Headaches, particularly during the first 1-2 weeks
Mild back pain or muscle cramps
Transient fatigue toward the end of longer cycles
Slight reduction in libido at higher doses or extended cycle lengths
Contraindications
Pre-existing liver disease or significantly elevated liver enzymes
Prostate cancer or breast cancer in males
Nephrotic phase of nephritis
Hypercalcemia (Anadrol can exacerbate calcium levels)
Pregnancy (Category X - causes virilization of the female fetus)
Known hypersensitivity to oxymetholone
Concurrent use of other 17-alpha alkylated oral steroids (compounded liver toxicity)
Active liver disease or significantly elevated liver enzymes
Hormone-sensitive cancers (breast, prostate) without oncologist clearance
Pregnancy or breastfeeding (potential endocrine disruption to fetus/infant)
Individuals under 21 years of age (risk of premature HPTA disruption during development)
Concurrent use of hepatotoxic medications without liver function monitoring
Known hypersensitivity to MK-2866 or any formulation excipients
Competitive athletes subject to WADA or USADA anti-doping testing
Research Evidence
Anadrol MK-2866
Status FDA Approved Moderate Research
References 5 studies 5 studies
Latest 2018 —
FDA Approved Yes No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.